Availability, cost and affordability of essential medicines for smoking cessation in low-income and middle-income countries: a cross-sectional study.

  • Catherine Plum
  • , Marie Stolbrink
  • , Obianuju Ozoh
  • , Shamanthi Jayasooriya
  • , Becky Nightingale
  • , Kevin Mortimer
  • , David Halpin

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Smoking cessation is more effective when supported by medicines. Data on the availability, cost and affordability of these treatments in low-income and middle-income countries (LMIC) are limited. Cross-sectional data for smoking cessation medications were collected from pharmacies, healthcare facilities and central medicine stores in 60 LMIC (2022–2023). Medications had varying availability, large price ranges and were essentially unaffordable. Enabling access to these medications is important in reducing tobacco consumption and associated disease. Strategies for integrating smoking cessation services into health systems are needed to reach Sustainable Development Goal targets.

Original languageEnglish
Article numberthorax-2024-222391
Pages (from-to)248-250
Number of pages3
JournalThorax
Volume80
Issue number4
DOIs
Publication statusPublished - 3 Mar 2025

Fingerprint

Dive into the research topics of 'Availability, cost and affordability of essential medicines for smoking cessation in low-income and middle-income countries: a cross-sectional study.'. Together they form a unique fingerprint.

Cite this